# Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

> **NCT03614156** · PHASE3 · TERMINATED · sponsor: **Naurex, Inc, an affiliate of Allergan plc** · enrollment: 363 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Rapastinel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03614156
- **Lead sponsor:** Naurex, Inc, an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-02
- **Primary completion:** 2019-07-11
- **Final completion:** 2019-07-11
- **Target enrollment:** 363 (ACTUAL)
- **Why stopped:** Business decision to stop the program.
- **Last updated:** 2020-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03614156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03614156, "Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03614156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*